Genetic susceptibility to psoriasis and psoriatic arthritis: Implications for therapy

British Journal of Dermatology

Volumn 166, Issue 3, 2012, Pages 474-482

  Hebert H L ^a   Ali, F R ^a   Bowes, J ^a   Griffiths, C E M ^a   Barton, A ^a   Warren, R B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN A; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

DISEASE PREDISPOSITION; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HERITABILITY; HUMAN; LIVER TOXICITY; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL AGENTS; DERMATOLOGIC AGENTS; FORECASTING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; METHOTREXATE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSORIASIS;

EID: 84857578523     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10712.x     Document Type: Review

References (69)

1. Brandrup F, Grunnet N, Henningsen K, et al. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 1982; 62: 229-36. (Pubitemid 12112914)
2. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64: ii14-17. (Pubitemid 40288513)
3. Moll JMH, Wright V,. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973; 32: 181-201.
4. Myers A, Kay LJ, Lynch SA, et al. Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology 2005; 44: 773-6. (Pubitemid 41487208)
5. White SH, Newcomer VD, Mickey MR, et al. Disturbance of HL-A antigen frequency in psoriasis. N Engl J Med 1972; 287: 740-3.
6. Russell TJ, Schultes LM, Kuban DJ,. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med 1972; 287: 738-40.
7. Karvonen J,. HL-A antigens in psoriasis with special reference to the clinical type, age of onset, exacerbations after respiratory infections and occurrence of arthritis. Ann Clin Res 1975; 7: 301-11.
8. Henseler T, Christophers E,. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-6. (Pubitemid 15016489)
9. Murray C, Mann DL, Gerber LN, et al. Histocompatibility alloantigens in psoriasis and psoriatic arthritis. Evidence for the influence of multiple genes in the major histocompatibility complex. J Clin Invest 1980; 66: 670-5. (Pubitemid 10060934)
10. Brenner W, Gschnait F, Mayr WR,. HLA B13, B17, B37 and Cw6 in psoriasis vulgaris: association with the age of onset. Arch Dermatol Res 1978; 262: 337-9. (Pubitemid 9014343)
11. Tiilikainen A, Lassus A, Karvonen J, et al. Psoriasis and HLA-Cw6. Br J Dermatol 1980; 102: 179-84. (Pubitemid 10148338)
12. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4: e1000041.
13. Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010; 42: 991-5.
14. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet 2009; 41: 199-204.
15. Zhang XJ, Huang W, Yang S, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 2009; 41: 205-10.
16. Huffmeier U, Uebe S, Ekici AB, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010; 42: 996-9.
17. Capon F, Bijlmakers MJ, Wolf N, et al. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet 2008; 17: 1938-45. (Pubitemid 351865842)
18. Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42: 985-90.
19. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997; 6: 1349-56. (Pubitemid 27351077)
20. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6: 813-20. (Pubitemid 27199077)
21. Oka A, Tamiya G, Tomizawa M, et al. Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. Hum Mol Genet 1999; 8: 2165-70. (Pubitemid 29525330)
22. Tazi Ahnini R, Camp NJ, Cork MJ, et al. Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Hum Mol Genet 1999; 8: 1135-40. (Pubitemid 29250903)
23. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006; 78: 827-51.
24. Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Investig Dermatol 2003; 120: 627-32. (Pubitemid 36344006)
25. Allen MH, Ameen H, Veal C, et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Investig Dermatol 2005; 124: 103-6. (Pubitemid 40100955)
26. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-90. (Pubitemid 46175676)
27. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-6. (Pubitemid 47241785)
28. Sun LD, Cheng H, Wang ZX, et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 2010; 42: 1005-9.
29. Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010; 42: 1000-4.
30. Smith RL, Warren RB, Eyre S, et al. Polymorphisms in the IL-12β and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Invest Dermatol 2008; 128: 1325-7. (Pubitemid 351543190)
31. Hollox EJ, Huffmeier U, Zeeuwen PLJM, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008; 40: 23-5.
32. Funk J, Langeland T, Schrumpf E, et al. Psoriasis induced by interferon-alpha. Br J Dermatol 1991; 125: 463-5.
33. Harrison PV, Peat MJ,. Effect of interferon on psoriasis. Lancet 1986; 2: 457-8. (Pubitemid 16039263)
34. Neumann R, Pohl-Markl H, Aberer E,. Parenteral interferon-alpha treatment of psoriasis. Dermatalogica 1987; 175: 23-8.
35. Quesada JR, Gutterman JU,. Psoriasis and alpha-interferon. Lancet 1986; 1: 1466-8. (Pubitemid 16095653)
36. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835-7.
37. Kadowaki N, Antonenko S, Lau JYN, et al. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000; 192: 219-25. (Pubitemid 30470304)
38. Bowes J, Flynn E, Ho P, et al. Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. Ann Rheum Dis 2010; 69: 2199-203.
39. Filer C, Ho P, Smith RL, et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008; 58: 3705-9.
40. Bowes J, Orozco G, Flynn E, et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 2011; 70: 1641-4.
41. Rahman P, Elder JT,. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64: ii37-9. (Pubitemid 40288518)
42. Gladman DD, Farewell VT,. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995; 38: 845-50.
43. Warren RB, Smith RL, Flynn E, et al. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Br J Dermatol 2011; 164: 660-4.
44. Eder L, Chandran V, Pellett F, et al. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2011; 70: 1594-8.
45. Bowes J, Eyre S, Flynn E, et al. Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis 2011; 70: 1016-19.
46. Jakobsdottir J, Gorin MB, Conley YP, et al. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet 2009; 5: e1000337.
47. Kraft P, Wacholder S, Cornelis MC, et al. Beyond odds ratios-communicating disease risk based on genetic profiles. Nat Rev Genet 2009; 10: 264-9.
48. Ryan C, Menter A, Warren RB,. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol Diagn Ther 2010; 14: 81-93.
49. Warren RB, Griffiths CEM,. The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. Br J Dermatol 2005; 153: 869-73. (Pubitemid 41540748)
50. Warren RB, Chalmers RJG, Griffiths CEM, et al. Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol 2008; 33: 551-4.
51. Warren RB, Smith RL, Campalani E, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008; 128: 1925-9. (Pubitemid 352001201)
52. Warren RB, Smith RL, Campalani E, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160: 438-41.
53. Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007; 127: 1860-7. (Pubitemid 47075365)
54. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5â tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898-904. (Pubitemid 36667162)
55. Gusella M, Bolzonella C, Crepaldi G, et al. A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele. Pharmacogenomics J 2006; 6: 421-4. (Pubitemid 44811538)
56. Chandran V, Siannis F, Rahman P, et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol 2010; 37: 1508-12.
57. Xiao H, Xu J, Zhou X, et al. Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 728-33.
58. Campalani E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006; 154: 345-52. (Pubitemid 43382709)
59. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2005; 126: 453-9.
60. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71. (Pubitemid 47069537)
61. Tejasvi T, Stuart P, Nair R, et al. Preliminary pharmacogenetic assessment of tumour necrosis factor (TNF) polymorphisms in psoriasis: response to anti-TNF and systemic therapies. Br J Dermatol 2008; 159: 1391 [Abstr.]
62. Seitz M, Wirthmüller U, Möller B, Villiger PM,. The -308 tumour necrosis factor-α-gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007; 46: 93-6. (Pubitemid 44932793)
63. Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008; 17: 3532-8.
64. Costanzo A, Talamonti M, Botti E, et al. HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis. Br J Dermatol 2008; 159: 1392 [Abstr.]
65. Ryan C, Kelleher J, Collins P, et al. A study to examine if the HLA-Cw 0602 allele is a predictor of response to TNF-α inhibitors in the treatment of psoriasis. Br J Dermatol 2009; 161 (Suppl. 1): 28 [Abstr.]
66. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44. (Pubitemid 8387357)
67. Gupta MA, Schork NJ, Gupta AK, et al. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol 1993; 28: 730-2. (Pubitemid 23133383)
68. Heller MM, Lee ES, Koo JY,. Stress as an influencing factor in psoriasis. Skin Therapy Lett 2011; 16: 1-4.
69. Cui J, Saevarsdottir S, Thomson B, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2010; 62: 1849-61.